Wyoming Drug Utilization Review (WY-DUR)

School of Pharmacy | College of Health Sciences

News

Preferred Drug List (PDL)

The Wyoming Medicaid Preferred Drug List (PDL) including step utilization for anti-depressant medications and prior authorization information is available at the Wyoming EqualityCare Pharmacy Provider website. To view the current PDL, please visit www.wymedicaid.org.

The Draft 2019 PDL, effective January 1, 2019, is available for review. Comments may be sent by email to alewis13@uwyo.edu or by mail to: Wyoming Drug Utilization Review Board, Dept. 3375, 1000 E. University Avenue, Laramie, WY 82071. Comments should be received prior to December 15, 2018.

Public Comment at Meetings:

A new policy for public comment at meetings is effective December 2, 2012.

PhRMA Guidelines and PhRMA Comment Request Form (updated November 5, 2015)

Public Guidelines and Public Comment Request Form (updated November 5, 2015)

Proposed Criteria

The following prior authorization criteria were approved at the November 8, 2018 P & T Committee meeting.

The 72 hour emergency fill policy will be applied to buprenorphine products, allowing pharmacies to override the PA process in an emergency situation to get patients started on therapy.

Antipsychotic medications, including long-acting injectables, will be limited to 100% of labeled dose. Patients currently above 100% will be reviewed and grandfathered as appropriate. Concurrent use of long-acting injectables and oral agents will require prior authorization with the exception of initiation of the injectable.

Concurrent use of different dosage forms of sumatriptan will no longer be allowed.

Aimovig and Ajovy will require a three-month trial and failure of both an anticonvulsant and a beta blocker. Concurrent use of botox will not be allowed. The Aimovig starting dose will be limited to 70 mg as there is no significant difference in efficacy, but a higher incidence of adverse effects with the 140 mg dose.

Orilissa, Mulpleta, Takhzyro, Lucemyra, and Palynziq will be limited to indication. Ilumya, Kevzara and Olumiant were referred to the Department of Health for cost analysis and PDL placement.

Baxdela will require a trial of Zyvox, ciprofloxacin or levofloxacin prior to approval.

Concurrent use of Lyrica and gabapentin will no longer be allowed. Both drugs will be limited to 100% of the labeled maximum.

Comments may be sent by email to alewis13@uwyo.edu or by mail to: Wyoming Drug Utilization Review Board, Dept. 3375, 1000 E. University Avenue, Laramie, WY 82071. Comments should be received prior to December 15, 2018.